These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 20959303)

  • 1. Views on lipid lowering. JUPITER seems to be bypassed.
    Murray SW
    BMJ; 2010 Oct; 341():c5835. PubMed ID: 20959303
    [No Abstract]   [Full Text] [Related]  

  • 2. Recent trials of lipid lowering.
    Ray KK; Cannon CP; Braunwald E
    Int J Clin Pract; 2007 Jul; 61(7):1145-59. PubMed ID: 17577297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Should the treatment of diabetic dyslipidemia be modified after the Action to Control Cardiovascular Risk in Diabetes Lipid study?].
    Pérez A
    Endocrinol Nutr; 2010 Dec; 57(10):457-9. PubMed ID: 20688585
    [No Abstract]   [Full Text] [Related]  

  • 4. Continuation of mortality reduction after the end of randomized therapy in clinical trials of lipid-lowering therapy.
    Kostis WJ; Moreyra AE; Cheng JQ; Dobrzynski JM; Kostis JB
    J Clin Lipidol; 2011; 5(2):97-104. PubMed ID: 21392723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [What has changed in therapy of vascular patients (role of statins and beta-adrenoblockers)].
    Pokrovskiĭ AV; Goloviuk AL
    Angiol Sosud Khir; 2010; 16(2):7-11. PubMed ID: 21032867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis.
    Marrs JC; Saseen JJ
    Pharmacotherapy; 2010 Aug; 30(8):823-9. PubMed ID: 20653359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Eicosapentaenoic acid ethyl esters].
    Ohtsuka S
    Nihon Rinsho; 2007 Jul; 65 Suppl 7():489-93. PubMed ID: 17824076
    [No Abstract]   [Full Text] [Related]  

  • 8. [ALLHAT [Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial]].
    Tomiyama H; Doba N
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():393-7. PubMed ID: 11347101
    [No Abstract]   [Full Text] [Related]  

  • 9. Prevention of cardiovascular disease utilizing fibrates--a pooled meta-analysis.
    Loomba RS; Arora R
    Am J Ther; 2010; 17(6):e182-8. PubMed ID: 20535009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of lipid-lowering drugs in children.
    Brown WV; Wilson DP; Freemark M; Kwiterovich PO
    J Clin Lipidol; 2010; 4(6):449-61. PubMed ID: 21122691
    [No Abstract]   [Full Text] [Related]  

  • 11. Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs.
    Laforest L; Souchet T; Moulin P; Ritleng C; Desamericq G; Le Jeunne P; Schwalm MS; Van Ganse E
    Arch Cardiovasc Dis; 2009 Jan; 102(1):43-50. PubMed ID: 19233108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary prevention in stroke. When we might extrapolate.
    Lewis LS
    BMJ; 2009 May; 338():b2097. PubMed ID: 19474012
    [No Abstract]   [Full Text] [Related]  

  • 13. Prevention of cardiovascular disease: plea for a rationale use of diet and lipid-lowering drugs.
    Scheen AJ
    Acta Clin Belg; 2003; 58(3):149-51. PubMed ID: 12945473
    [No Abstract]   [Full Text] [Related]  

  • 14. Trial clouds use of niacin with a statin.
    Harv Heart Lett; 2011 Aug; 21(12):2. PubMed ID: 21991606
    [No Abstract]   [Full Text] [Related]  

  • 15. Using both "relative risk reduction" and "number needed to treat" in evaluating primary and secondary clinical trials of lipid reduction.
    Moriarty PM
    Am J Cardiol; 2001 May; 87(10):1206-8; A7. PubMed ID: 11356401
    [No Abstract]   [Full Text] [Related]  

  • 16. Framing cardiovascular disease event risk prediction.
    Stone JA
    Can J Cardiol; 2011; 27(2):171-3. PubMed ID: 21459265
    [No Abstract]   [Full Text] [Related]  

  • 17. Results of the REVEAL study. Why Should we not welcome a new lipid lowering agent?
    Masana L
    Clin Investig Arterioscler; 2017; 29(6):278-279. PubMed ID: 29173491
    [No Abstract]   [Full Text] [Related]  

  • 18. Fibrate use in diabetes: new concepts.
    Bloomgarden ZT; Drexler A
    J Diabetes; 2011 Mar; 3(1):1-2. PubMed ID: 21159144
    [No Abstract]   [Full Text] [Related]  

  • 19. Niacin: the only vitamin that reduces cardiovascular events.
    Wierzbicki AS
    Int J Clin Pract; 2011 Apr; 65(4):379-85. PubMed ID: 21401825
    [No Abstract]   [Full Text] [Related]  

  • 20. Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal.
    de Lorgeril M; Salen P; Abramson J; Dodin S; Hamazaki T; Kostucki W; Okuyama H; Pavy B; Rabaeus M
    Arch Intern Med; 2010 Jun; 170(12):1032-6. PubMed ID: 20585068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.